No. We need approvals, coupled with the miracle of either very few competitors or being first-to-file (*), coupled wiith the partner company bothering to make the necessary effort. Lots of ducks have to align.
(*): And the avalanche of competiitors from India, which not only have cost effective manufacturing capability, but also are very capable drug developers. The flip side of the generics FDA approval flood-gates opening in the last several years, is that it's also opened the flood gates of players (esp from India) chasing the US gravy train.
Ann: Acrux presentation at Hidden Gems in Lifesciences Forum, page-23
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
-0.001(5.00%) |
Mkt cap ! $7.747M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.0¢ | 1.9¢ | $13.72K | 687.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 618035 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 234041 | 2 |
View Market Depth
| Last trade - 14.19pm 18/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |